Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis

Patera, A.C.; Menzel, F.; Jackson, C.; Brieland, J.K.; Halpern, J.; Hare, R.; Cacciapuoti, A.; Loebenberg, D.

Antimicrobial Agents and ChemoTherapy 48(8): 3154-3158

2004


ISSN/ISBN: 0066-4804
PMID: 15273138
DOI: 10.1128/aac.48.8.3154-3158.2004
Accession: 004122246

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Using an inhalation model of pulmonary aspergillosis, we observed modest differences in the survival rates of mice treated with granulocyte colony-stimulating factor (G-CSF) and posaconazole (POS) and those treated with POS alone. This finding is in contrast to a previous report that suggested that G-CSF had a significant antagonistic effect on the antifungal activity of POS.